Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma

NCT ID: NCT07183852

Last Updated: 2025-09-19

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2026-03-31
• Study Completion Date: 2033-03-31

Brief Summary

The purpose of this study is to evaluate the feasibility, safety and tolerability of locoregional or systemic administration of autologous tumor infiltrating lymphocytes in patients with metastatic melanoma

Conditions

Metastatic Uveal Melanoma; Metastatic Cutaneous Melanoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Patients With Uveal Melanoma and Liver Metastases, locoregional admin using HAI

Group Type: EXPERIMENTAL

Autologous Tumor Infiltrating Lymphocytes (TIL)

Intervention Type: DRUG

Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion

Melphalan

Intervention Type: DRUG

1 mg/kg, IV

Interleukin-2

Intervention Type: DRUG

2 MIU, subcutaneous twice daily for up to 14 days.

Cohort 2

Patients With Cutaneous Melanoma and visceral metastases, IV admin

Group Type: EXPERIMENTAL

Autologous Tumor Infiltrating Lymphocytes (TIL)

Intervention Type: DRUG

Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion

Melphalan

Intervention Type: DRUG

1 mg/kg, IV

Interleukin-2

Intervention Type: DRUG

2 MIU, subcutaneous twice daily for up to 14 days.

Interventions

Autologous Tumor Infiltrating Lymphocytes (TIL)

Cohort 1: Administered via hepatic arterial infusion Cohort 2: Administered via intravenous infusion

Intervention Type: DRUG

Melphalan

1 mg/kg, IV

Intervention Type: DRUG

Interleukin-2

2 MIU, subcutaneous twice daily for up to 14 days.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Participants must be at least 18 years of age.

2. Can provide a signed informed consent as described in the protocol, including compliance with the requirements and restrictions listed in the ICF and in this protocol.

3. World Health Organization (WHO) Performance Status 0 or 1.

4. Patient must have a histologically/cytologically confirmed diagnosis of:

• stage IV uveal melanoma with confirmed progression following prior systemic therapy with tebentafusp (if HLA A2:01 positive) OR
• stage IV cutaneous melanoma with confirmed progression following prior systemic therapy with a programmed cell death protein-1 (PD-1) inhibitor with or without a CTLA-4 inhibitor

5. At least one resectable lesion in the liver (or aggregate of lesions resected) of a minimum size of 0.5 cm in diameter to generate TILs.

6. Measurable disease by computed tomography (CT) per RECIST 1.1 criteria after resection of lesion for TILs production

7. No other malignancies, except if treated with curative intent and with a cancer-related life expectancy of more than 5 years.

8. Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

9. Female patients of childbearing potential must be willing to use a highly efficient method of contraception (Pearl index <1), for the course of the study through 120 days after the last dose of study medication.

10. Male patients with women of childbearing potential partners must agree to use a condom for contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.

Exclusion Criteria

1. Any serious or uncontrolled medical conditions that, in the investigator's opinion, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy (including operation), or interfere with the interpretation of study results.

2. Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

3. Women who are pregnant or breastfeeding.

4. Any condition that potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the subject before registration in the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Vastra Gotaland Region

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Lars Ny, PhD

Role: CONTACT

lars.ny@vgregion.se

+46 31 342 40 11

Axel Nelson, PhD

Role: CONTACT

axel.nelson@vgregion.se

+46 31 342 40 11

Other Identifiers

GoTIL_2025EU

Identifier Type: -

Identifier Source: org_study_id